Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells

Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells

Anti-tumor mAbs are the most widely used and characterized cancer immunotherapy. Despite having a significant impact on some malignancies, most cancer patients respond poorly or develop resistance to this therapy. A known mechanism of action of these therapeutic mAbs is antibody-dependent cell-media...

Full description

Bibliographic Details
Main Authors: Kristin M. Snyder, Robert Hullsiek, Hemant K. Mishra, Daniel C. Mendez, Yunfang Li, Allison Rogich, Dan S. Kaufman, Jianming Wu, Bruce Walcheck
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Immunology
Subjects:
FcR
ADCC
NK cell
immunotherapy
antibody
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02873/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02873/full

Similar Items